# Adenoviral vectors: the delivery workhorse of genetic vaccines and gene therapy

How replication-deficient adenoviral vectors work, why suspension bioreactors and the plasmid-to-vector GMP chain decide who can manufacture them, and what platform families like Ad5 and GRAd actually share.

An adenoviral vector is a virus stripped of its replication machinery and re-tasked as a delivery vehicle; the field's science is the capsid's tolerability, its industry is suspension-scale GMP, and its quiet precondition is an industrial plasmid supply.

Source: https://en.bioecon.ru/docs/health-biomedicine/therapeutics-platforms/adenoviral-vector-gene-therapy/
Updated: 2026-09-18



An adenoviral vector is a deal struck with a common pathogen. The virus is reduced to a delivery shell — replication genes removed so the particle can enter a cell, hand over an expression cassette, and go no further — and the deleted capacity is spent carrying cargo: an antigen gene for a vaccine, a corrective gene for a therapy. The host cell does the rest, which is why the platform reads like a manufacturing contract rather than a drug design. Immunogenicity, once the obstacle, became a feature: a vector that provokes innate attention is exactly what a vaccine wants, and the same property is what gene-therapy programs must manage down.

The industrial logic rests on one biological fact: adenoviruses grow to high titers in suspension culture. That single property moved vector manufacturing out of adherent-cell factories and into single-use bioreactors measured in thousands of litres, which is why a mid-size European pure-play can promise batch fill-finish of up to 3,500 vials from 2,000 L behind six isolated GMP suites of 3,470 square metres. Scale is not the whole story, because a vector campaign inherits its quality from its inputs. The expression cassette arrives as GMP-grade plasmid DNA, and plasmid supply industrialized on its own schedule: a dedicated commercial plasmid facility of 6,400 square metres in Zhenjiang now backs 16,000 litres of GMP capacity that has carried more than 140 IND clearances — the quiet precondition of every vector program behind it.

Platform families are where the economics compound. One capsid backbone, re-targeted by swapping the expression cassette, serves a vaccine against one pathogen, a vaccine against another, and a gene-therapy indication after that. CanSino Biologics built its position as a global pioneer of adenoviral-vector vaccines on the Ad5 platform and now couples it to lines in Mexico, Pakistan and Malaysia, a Shanghai facility sized for 100 million doses per year, and the market-by-market certificate stack — Malaysian NAPRA GMP, Indonesian Halal certification — that commercial supply at population scale actually requires. ReiThera's GRAd line descends from the Okairos team GSK acquired in 2014, with platforms validated alongside GSK and in large COVID-19 vaccine trials. OBiO Technology in Shanghai packages plasmid, AAV, lentiviral and adenoviral vectors from research grade through GMP Phase I–III to commercial supply, reporting a fully commercial closed loop in 2026.

What the platform cannot yet do is worth stating plainly. Adenoviral immunity in the human population is real, so repeat dosing runs against pre-existing antibodies — the reason higher-serotype and chimpanzee-derived backbones exist at all. Transgene size fits inside the capsid's fixed budget. And the delivery is episodic: the vector does what it is asked once, then the immune system clears the machinery. The field's answers — platform families, alternative serotypes, immune-management regimens — are engineering around a biology that is unlikely to be argued away. The manufacturing map, not the capsid map, is where the field's near-term competition is being decided: who can run suspension GMP at 2,000 litres, feed it from an industrial plasmid plant, and put fill lines close to the markets their certificates must satisfy.